Table II.
Reference | N | Predominant RIC Regimen | MRD/MUD | MMRD/MMUD | Haplo | Engrafted (%) | Mixed Chimerism (%) | Graft-Related Acute GVHD (I-IV or II-IV) | HLH post-HCT (%) | VOD (%) | Death Prior to Day +100 | Predominant Causes of Death | Survival (years) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cooper et al (2006) | 12 | Alem, Flu, Mel *Haplos received ATG instead of alem, and also busulfan | 50% | 25% | 25% | 100% | 33% | 33% | Not Specified | 0% | Not Specified | Pneumonitis | 75% (30-month Median Follow-Up) |
Cooper et al (2008) | 25 | Alem, Flu, Mel *Haplos received ATG instead of alem, and also busulfan | 40% | 44% | 16% | 100% | 29% | Not Specified | 0% | 0% | Not Specified | Pneumonitis | 84% (3- year Median Follow-Up) |
Marsh et al (2010b) | 26 | Alem, Flu, Mel | 73% | 27% | 0% | 100% | 65% | 8% | 4% | 0% | 0% | Infection, GVHD | 92% (3-year POS) |
RIC Reduced intensity conditioning
MRD Matched related donor
MUD Matched unrelated donor
MMRD Mismatched related donor
MMUD Mismatched unrelated donor
Haplo Haploidentical
GVHD Graft-versus-host disease
HLH Haemophagocytic lymphohistiocytosis
HCT Haematopoietic cell transplantation
VOD (hepatic) Veno-occlusive disease
Alem Alemtuzumab
Flu Fludarabine
Mel Melphalan
POS Probability of survival